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Abstract
Background Thislargepopulation-basedstudywasconducted
to estimate the prevalence of Dupuytren’s disease in US adults
and describe associated treatment patterns.
Methods A total of 23,103 individuals from an Internet-
based research panel representative of the US population
completed a brief online survey designed to identify
individuals with symptoms, diagnoses, and/or treatment
experience indicative of Dupuytren’s disease (mean age =
50 years).
Results The prevalence of Dupuytren’s disease defined as a
self-reported physician diagnosis and/or surgical treatment
was estimated as 1% (95% CI = 0.8–1.2), but the estimated
prevalence is much higher (7.3%) when including self-
reported symptoms of ropelike growth or hard bumps on
the hand. The annual incidence proportion was estimated at
about 3 cases per 10,000 adults. A total of 326 participants
who reported relevant Dupuytren’s symptoms, treatment,
and/or diagnosis completed a more in-depth survey focus-
ing on timing of medical treatments after first symptom
noticed, description of functional impairment, treatment
patterns, and family history. From the second survey, most
patients who reported seeking treatment for hand symptoms
initially saw a primary care physician, and the mean time
from noticing the first hand symptom to seeing a doctor
was 23.1 months. At their first doctor visit for hand
symptoms, only 9% of patients received a diagnosis of
Dupuytren’s disease and 48% were advised to “wait and
see” or received no treatment.
Conclusions Results from the current study indicate a
number of unmet medical needs, so strategies to raise
physician awareness of disease symptoms and effective
treatment options may be helpful.
Keywords Dupuytren’s.Prevalence.Incidence.United
States.Survey.Treatment.Epidemiology
Background
Dupuytren’s disease, also called Dupuytren’s contracture or
palmar fibromatosis, is a condition in which the connective
tissue under the skin of the palm contracts and toughens
over time [2]. The fibroproliferative disorder affects the
palmar fascia; ropelike collagen cords form, thicken, and
shorten, causing permanent flexion contractures of joints
and progressive flexion of one or more fingers. Typically,
the metacarpophalangeal joint, the proximal interphalangeal
joint, or both joints are involved, and contractures ulti-
mately lead to hand deformity and impaired hand function
[15]. The typical symptom is the presence of a nodule on
the hand (a small knot or knob) followed by the formation
of a ropelike growth on the palm (cord) and then permanent
contracture of the fingers. Dupuytren’s disease usually
presents in one hand first, and at some later time may
appear in the other hand [2, 15]. Thickening of the lines in
the palms of the hands or on knuckles and skin pitting and
dimpling may also be present [21].
A recent review of epidemiologic studies of Dupuytren’s
found that the majority have been conducted in Scandinavia
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review, the prevalence estimates of Dupuytren’s disease
varied from 0.2% [8] to 56% [4]; the large range was
attributed to variation in age, population groups, and
methods of data collection. Given that the prevalence of
Dupuytren’s disease has been shown to have large
geographic variability, likely due to genetic and environ-
mental differences [10], the epidemiological data from
other countries should not be applied to the US population.
Using a Web-based survey design, the current study sought
to estimate the prevalence and 1-year incidence proportion
of Dupuytren’s disease in the general US population,
describe hand symptom characteristics and functional
impairment, and determine the time from first symptom
noticed to medical treatment, treatment patterns, and family
history.
Materials and Methods
Study Design
This cross-sectional, population-based survey was con-
ducted in two phases (Fig. 1). In the initial phase (phase
1), panel participants from Knowledge Networks’ (KN)
online panel were screened for the presence of current
symptoms of Dupuytren’s disease, past surgical and/or
needle aponeurotomy treatments, and a diagnosis of the
disease. Data from phase 1 were used to estimate the
prevalence of Dupuytren’s disease in the general US
population and to determine eligibility to complete the full
survey phase (phase 2). In phase 2, a subsample of
participants meeting the eligibility criteria for Dupuytren’s
disease were invited to complete the Dupuytren’s disease
survey, which collected detailed information on severity of
symptoms, timing and type of first symptoms noticed,
treatment-seeking patterns, diagnoses, and brief medical
and family histories. Phase 1 also collected information on
Peyronie’s disease, and a parallel Peyronie’s disease survey
was conducted in phase 2. Details and results regarding
Peyronie’s disease are not reported in this paper, but will be
reported in a future publication.
The KN panel, a proprietary Web-enabled panel of
individuals who have agreed to participate in ongoing
survey research, is the only known online panel based on
a random-digit-dialing sample of the full US population,
ensuring that the panel is representative of the US
population [13]. KN provides panelist “points” that can
be redeemed for cash at regular intervals for panel
participation (for those with Internet access) or with
Web-enabled technology to ensure that those who would
not otherwise have access to the Internet are able to
participate in KN surveys. The KN panel has been used to
estimate prevalence previously in several different studies
[19, 20, 24].
Following ethics committee approval, screening in phase
1 was fielded from 6 November 2007 through 9 December
2007, and the full survey in phase 2 was fielded from 20
March 2008 through 31 March 2008.
Screening 
Population
32,000 panel participants
Phase 1
23,103 participants 
completed Phase 1 survey 
Phase 2
2,813 participants were 
eligible for Phase 2 survey
Phase 2
Subsample
a
Treatment and/or 
diagnosis of 
Dupuytren’s 
reported in 
Phase 1
(n=197)
Phase 2
Subsample
a
Random selection 
of those reporting 
Dupuytren’s 
symptoms in 
Phase 1 
(n=266)
Fig. 1 Study design. Data for this study were collected in two phases.
In phase 1, panel participants were screened for the presence of
symptoms, past treatment, and a diagnosis of Dupuytren’s disease. In
phase 2, eligibility to complete the full survey was determined by
participants’ responses to the screening items in phase 1.
aParticipants
for the Dupuytren’s phase 2 subsample populations were selected from
the phase 2 eligible participants population to meet predetermined
sample sizes
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A total of 32,000 men and women aged 18 years and older
residing in the USA were randomly selected from the KN
online panel and invited to participate in the current study.
Eligibility for the Dupuytren’s disease full survey (phase 2)
was based on responses to the screening questions in phase
1. Specifically, phase 1 respondents eligible for the
Dupuytren’s disease phase 2 survey were those who
reported one or more of the following criteria at screening:
1. Ever received a diagnosis of Dupuytren’s disease or
Dupuytren’s contracture by a doctor or other healthcare
professional
2. Ever received either surgery or a needle aponeurotomy
(or needle fasciotomy) to treat a hard, ropelike growth
in the palm
3. Currently have at least one of the following symptoms:
& A hard bump (knot) that developed on the palm or
at the base of the fingers (excluding calluses, warts,
or bumps caused by work done with hands)
& A hard, ropelike growth (cord) that developed in
the palm of the hand
Note that participants who reported only dimpling in
phase 1 had the potential for inaccurate identification of
that symptom and thus were excluded from completing the
survey in phase 2. Individuals who met the eligibility
criteria for the phase 2 survey will be referred to as
Dupuytren’s patients, unless otherwise specified.
Sampling Method for the Phase 2 Dupuytren’s Disease
Survey
Patients invited to participate in phase 2 were selected using
a stratified random sampling approach based on the
following two strata within each disease: (1) participants
reporting treatment (surgery or needle aponeurotomy) and/
or diagnosis (stratum 1, meeting criteria 1 and 2) and (2)
participants reporting symptoms (a ropelike growth or a
hard bump) only (stratum 2, meeting criterion 3). To ensure
an adequate sample size to evaluate treatment patterns, all
eligible respondents in stratum 1 were invited to complete
the phase 2 Dupuytren’s disease survey. In addition, a
portion of respondents (n=266) from stratum 2 were
randomly selected to participate in the phase 2 survey.
Because no respondents were allowed to complete both
Dupuytren’s and Peyronie’s disease surveys, for the few
respondents who were eligible to participate in both
surveys, priority was given to the rarer Peyronie’s disease.
As a result and a limitation, 4% of the eligible Dupuytren’s
patients were not covered in the Dupuytren’ss u r v e y
sample.
Questionnaire Content
The phase 1 questionnaire included questions assessing
t h ep r e s e n c eo fv a r i o u sh a n d - r elated symptoms, diagnosis
of Dupuytren’s disease or Dupuytren’s contracture, and
past surgical procedures or needle aponeurotomy treat-
ments for hand-related symptoms. Real-life pictures
corresponding with each symptom [ropelike growth
(cord), hard bump, and dimpling] were included in the
screener to help patients accurately assess the presence of
these symptoms.
The Dupuytren’s survey developed specifically for the
phase 2 portion of this study focused on the presence and
severity of current symptoms, family history, and treatment
history for hand symptoms (e.g., specific symptom first
noticed, time from noticing first symptom until seeking
medical treatment, other symptoms noticed, types of
treatment received and success of each treatment type,
length of treatment/duration of care, number of surgeries
and/or needle aponeurotomies, diagnoses received, types of
physicians treating and/or diagnosing the disease).
Data Analysis
Prevalence Estimates
The prevalence estimates of Dupuytren’sd i s e a s ew e r e
based on self-reported data from phase 1 and adjusted to
represent the US population by using statistical weights
provided by KN. These weights are designed to (1)
account for the known sources of deviation from an
equal-probability selection design during formation of the
KN panel, (2) reduce bias due to noncoverage of
households without telephones, and (3) reduce the
nonresponsebiaspotentiallyintroducedduringdatacollection
for outcomes highly correlated with demographic and
geographic characteristics.
Five different prevalence estimates for Dupuytren’s
disease were calculated. The numerators for the prevalence
estimates of Dupuytren’s disease were derived using the
following five definitions, ordered from the most to the
least stringent, and the denominator was the number of
individuals who completed phase 1:
& Definition 1: Patient has received a diagnosis of
Dupuytren’s disease or Dupuytren’s contracture from a
doctor or other healthcare professional
& Definition 2: Patient meets the criterion in definition 1
or has ever had surgery and/or a needle aponeurotomy
to treat a hard, ropelike growth in the palm of the hand
& Definition 3: Patient meets the criteria in definition 2 or
has a hard, ropelike growth (like a cord) in the palm of
the hand
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has a hard bump (like a knot) on the palm or at the base
of finger
& Definition 5: Patient meets the criteria in definition 4 or
has noticeabledimpling (like a pit)on the skinof the palm
Note that the definition 5 is the least stringent definition
and includes patients who reported only dimpling in phase 1.
These patients were excluded from completing the survey in
phase 2, as discussed previously. Although the incidence
proportion of Dupuytren’s disease based on definition 5 was
not available, the corresponding prevalence estimate is
provided from screening data from phase 1.
Incidence Proportion
The 1-year incidence proportion for Dupuytren’s disease in
2007 was based on (1) time of first diagnosis by a doctor or
other healthcare professional (corresponding to definition 1)
and (2) the earliest time when a hard bump or ropelike
growth was noticed (corresponding to definition 4). The
incidence proportion was defined as the number of new
cases, i.e., participants who reported 2007 as their year of
onset (diagnosis or symptom), divided by the number of
people who were free of the condition (i.e., at risk of
developing the condition) on the first day of 2007. It is a
function of the prevalence and the proportion of new cases
among all cases. The prevalence was estimated using data
from phase 1 as described previously. The proportion of
new cases among all cases was estimated using data from
the survey completed in phase 2.
Analysis of Phase 2 Dupuytren’s Disease Survey
Because patients reporting a diagnosis or treatment (stratum
1) were oversampled in the phase 2 survey, to get an unbiased
estimate for the Dupuytren’s patients (definition 4), summary
statistics (e.g., mean, standard error, or percentage) of disease
symptoms, family history, and treatment patterns collected in
thephase2surveywerecalculatedusingweightedaveragesof
the stratum-specific estimates [9]. The weight for each
stratum was the proportion of the respondents in the stratum
among Dupuytren’s patients, which was estimated using
phase 1 data. No imputations were made for missing values.
When calculating percentages, patients who did not answer a
particular question were excluded from the denominator for
that question.
Results
Of the 32,000 men and women (16,000 of each gender)
aged 18 years and older who were randomly selected from
the pool of KN panel members and invited to participate in
phase 1, a total of 23,103 completed the screening survey
for a response rate of 72%. Over 400 (n=463) Dupuytren’s
patients (197 of them reported a Dupuytren’s diagnosis and/
or surgical/needle aponeurotomy treatment) were invited to
complete a full survey in phase 2; of those, 376 (81%)
responded to the survey invitation. Of the responders, 326
(87%) consented and completed the Dupuytren’s disease
survey in phase 2.
Demographic Characteristics
Table 1 presents unweighted demographic characteristics
for all respondents in phase 1 as well as respondents to the
Dupuytren’s disease survey in phase 2. The mean age of all
respondents in phase 1 was nearly 50 years (range, 18–
101 years), similar to the phase 2 respondents reporting
only symptoms (mean age, 49 years). Those reporting a
diagnosis or treatment were older on average (mean age,
59 years) and had a higher proportion of males (63%)
compared with the general participants or those with only
symptoms. The majority of respondents across both phases
were white and had completed more than a high school
level of education.
Prevalence and Incidence Proportion
The estimated prevalence of Dupuytren’s based on the five
definitions ranged from 0.5% to 11% (Table 2). The
estimated prevalence is <1% based on self-reported
diagnosis of Dupuytren’s disease or Dupuytren’s contrac-
ture, and only 1% based on self-reported diagnosis and/or
surgery/needle aponeurotomy (or fasciotomy). The estimated
1-year incidence proportion of Dupuytren’s (number of new
cases in 2007/size of the population at risk at the beginning of
2007) rangedfrom0.03% for the first diagnosis bya doctoror
other healthcare professional to 1.4% for the first symptom
noticed (hard bump or ropelike growth; Table 3)[ 23]. The
estimated annual number of new cases of physician-
diagnosed Dupuytren’s, based on the year 2007 data, was
approximately 3 cases per 10,000 adults (or 70,505 adults
based on current census data) [23]. If first symptoms noticed
was used, the estimated annual number would be 140 cases
per 10,000 adults (or 3,290,224 adults).
Dupuytren’s Disease Symptoms and Family History
Table 4 presents the weighted estimates of the disease
symptoms among the Dupuytren’s patients (definition 4).
The most commonly reported symptom at the time of the
survey was a hard bump on one or both hands (69%),
followed by dimpling in one hand (30%) and a ropelike
growth (cord) in one hand (23%, Table 4). More than one
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were bent to the extent that it interfered with everyday
activities, such as picking up items, putting on gloves,
buttoning a shirt, or washing hands or face (data not shown
in table).
The first hand symptom noticed was most commonly a
bump or a knot that had developed on the palm or at the
base of the fingers (61%). A substantially lower percentage
of Dupuytren’s patients reported that a ropelike growth was
the first symptom noticed, followed by fingers bent toward
the palm or dimpling (Table 4). Nearly all Dupuytren’s
patients (82%) indicated that the first symptom noticed
appeared only in one hand.
Eighteen percent of Dupuytren’s patients reported that an
immediate family member had one or more symptoms
consistent with Dupuytren’s: hard bump (10%), bent fingers
(9%), dimpling (5%), and a ropelike growth (5%). Only 3%
of patients indicated that an immediate family member had a
diagnosis of Dupuytren’sd i s e a s e ,D u p u y t r e n ’sc o n t r a c t u r e ,o r
palmar fibromatosis.
Dupuytren’s Disease Treatment Patterns
One hundred ninety-two Dupuytren’sp a t i e n t sr e p o r t e ds e e i n g
a doctor for the treatment of hand symptoms. Of these, 63%
talkedtoadoctorwhenahandsymptomwasfirstnoticed,and
37% spoke to a doctor at a later date. Of these treatment-
seeking patients, 70% initially sought treatment from a
primary care physician (PCP). Only 12% sought initial
treatment from a hand specialist/hand surgeon. The remaining
Disease definition Phase 1 participants (N=23,103)
Prevalence (%) 95% CI
Definition 1: Diagnosis 0.5 0.4–0.7
Definition 2: Diagnosis or treatment 1.0 0.8–1.2
Definition 3: Diagnosis, treatment, or ropelike growth 3.0 2.7–3.3
Definition 4: Diagnosis, treatment, ropelike growth, or hard bump 7.3 6.8–7.8
Definition 5: Diagnosis, treatment, or any symptom 10.9 10.3–11.5
Table 2 Estimated prevalence
of Dupuytren’s disease in the
United States in 2007
Prevalence estimates are
weighted estimates from 23,103
respondents
CI confidence interval
Table 1 Summary of demographic characteristics
Characteristic Phase 1 participants (N=23,103) Phase 2 participants (N=326)
With hard bump or ropelike growth
and no diagnosis/treatment (n=161)
With diagnosis/treatment
(n=165)
Age (years), n (%)
18–29 2201 (10) 27 (17) 6 (4)
30–44 7165 (31) 37 (23) 19 (12)
45–59 7112 (31) 47 (29) 56 (34)
60+ 6625 (29) 50 (31) 84 (51)
Gender, n (%)
Male 11,420 (49) 73 (45) 104 (63)
Female 11,683 (51) 88 (55) 61 (37)
Race, n (%)
White, non-Hispanic 18,735 (81) 127 (79) 132 (80)
Black, non-Hispanic 1,788 (8) 12 (7) 10 (6)
Other, non-Hispanic 615 (3) 7 (4) 9 (5)
Hispanic 1,342 (6) 14 (9) 6 (4)
2+ races, non-Hispanic 623 (3) 1 (1) 8 (5)
Education, n (%)
Less than high school 1,421 (6) 23 (14) 11 (7)
High school 5,592 (24) 46 (29) 36 (22)
Some college 7,634 (33) 44 (27) 50 (30)
Bachelor’s degree or higher 8,456 (37) 48 (30) 68 (41)
HAND (2011) 6:149–158 15318% sought initial treatment from an orthopedic specialist/
orthopedic surgeon, plastic surgeon, rheumatologist, or other
type of healthcare professional.
The mean time from noticing the first hand symptom to
seeing a doctor was 23.1 months (SE = 5.6 months). The
most common first symptom that led patients to seek
treatment was a hard bump (48%), followed by ropelike
growth (12%), pit or dimpling (11%), and bent fingers
(10%). Only 9% of patients seeking treatment for a hand
symptom received a diagnosis of Dupuytren’s from the first
doctor. Other diagnoses received from the first doctor seen
included arthritis/rheumatoid arthritis (25%), carpal tunnel
(22%), tendonitis (15%), ganglia (10%), and trigger finger
(10%), and 12% reported some “other” diagnosis. The first
physician seen for a hand symptom provided an average
duration of care of approximately 8.6 months.
Among those patients who sought treatment for a hand
symptom, 48% were either told by the first doctor seen to
“wait and see” or simply received no treatment; others
received physical therapy, splint, steroid injection, prescrip-
tion medication, over-the-counter medication, surgery,
needle aponeurotomy, other treatment, or referral to a
specialist. Of the 101 patients who reported receiving at
least one treatment, the most commonly reported first-time
treatments were prescription medication (40%), physical
therapy (21%), splinting (19%), steroid injection (19%),
surgery (18%), and over-the-counter medication (10%, data
not shown in table). These were also most commonly
reported as the second treatment. Very few patients received
more than two treatments (n<15). Table 5 presents the most
commonly reported treatments received anytime after
seeing a doctor. The mean time from noticing the first
symptom until receiving the first treatment ranged from
7 months (SE=4.9) for referral to a specialist to more
than 7 years for over-the-counter medication (data not
s h o w ni nt a b l e ) .
Among patients with a Dupuytren’s diagnosis (n=93),
over half (52%) received the diagnosis from their PCP.
Table 4 Summary of current Dupuytren’s disease symptoms among Dupuytren’s patients
Survey question Statistic or category % of Participants (n=326)
Hard bump (knot) on the palm or at the base of fingers In one hand 46
In both hands 23
Dimpling (pit) on the skin of palm In one hand 30
In both hands 21
Ropelike growth (cord) in the palm of hand In one hand 23
In both hands 14
One or more finger(s) bent toward palm In one hand 20
In both hands 19
Able to flatten palm on an even surface Can flatten both palms 74
Can flatten palm of one hand only 20
Cannot flatten either palm 7
Hand symptom noticed first A hard bump (knot) 61
A hard, ropelike growth (cord) 12
One or more finger(s) bent toward palm 11
Dimpling (pit) 9
Other 6
Percents are weighted averages of the stratum-specific estimates
Table 3 Estimated incidence proportion of Dupuytren’s disease in the United States in 2007
Dupuytren’s disease Incidence proportion (%) 95% CI Current US population estimate
a
First diagnosed 0.028 0.000–0.078 70,505 adults
First symptom
b noticed 1.442 0.907–1.977 3,290,224 adults
Incidence estimates are weighted estimates from 23,103 respondents in phase 1 and 326 respondents in phase 2
CI confidence interval
aBased on current extrapolated US population data (18 years and over): 235,016,000 adults [23]
bHard bump or ropelike growth
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included hand specialist/surgeons (20%) and orthopedic
specialist/orthopedic surgeons (16%).
Summary of Surgical Procedures
Of the Dupuytren’s patients reporting seeing a doctor, 20%
reported they had received surgery to treat a hand symptom;
of these, 62% reported one surgery, 29% reported two
surgeries, and 9% reported three or more surgeries (Table 6).
Hand specialists or hand surgeons performed nearly two
thirds (62%) of first-time surgeries and orthopedic specialists
or surgeons performed 27% of first-time surgeries.
The type of surgery performed was unknown to 40% of
Dupuytren’s patients, 16% of patients reported complete
fasciectomy, 7% reported partial fasciectomy, and 12%
reported percutaneous fasciotomy. Of those Dupuytren’s
patients who reported the time of surgery and the first-noticed
hand symptom or diagnosis (n=68), the mean time from first
noticing a hand symptom until first surgery was 18.1 months
(SE=3.5 months), and the mean time from first diagnosis to
first surgery (n=25) was 8.8 months (SE=2.9 months).
Table 5 Treatment among patients reporting a doctor visit for the treatment of a hand symptom (n=192)
Most commonly reported treatment Patients reporting treatment (%) Time to first treatment since first symptom (months)
N Mean (SE) Range
Prescription medication 30 32 28.2 (11.0) 0–150
Surgery 20 54 28.2 (15.2) 0–151
Steroid injection 19 23 19.1 (6.4) 0–120
Physical therapy 18 22 31.4 (17.0) 0–147
Splint 16 27 28.0 (15.7) 0–148
Time to first treatment is summarized among those receiving treatment. Percent, mean, and SE are weighted averages of the stratum-specific
estimates
SE standard error
Table 6 Summary of hand surgeries and needle aponeurotomies used to treat hand symptoms
Patients who had surgery
(n=89)
Patients who had a needle aponeurotomy
(n=44)
No. of procedures
1 55 (62%) 25 (57%)
2 26 (29%) 14 (32%)
3 4 (4%) 3 (7%)
4 2 (2%) 0 (0%)
5 or more 2 (2%) 2 (5%)
Did the first procedure correct the problem?
Yes 71 (80%) 17 (39%)
Hand symptoms after first procedure
Symptoms returned in the same place 14 (20%) 3 (18%)
Symptoms appeared in a new spot on same hand 9 (13%) 2 (12%)
Symptoms appeared in other hand 18 (25%) 3 (18%)
Symptoms did not come back and no new symptoms have appeared 34 (48%) 10 (59%)
How soon symptoms returned after surgery
No. of patients whose symptoms returned in the same place 14 3
Months till return, mean (SE) 44.1 (10.6) 26.3 (17.2)
Months till return, median 30.0 16.0
Percentages are calculated from the single stratum (patients having had surgery or a needle aponeurotomy to treat a hand symptom)
SE standard error
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Of the Dupuytren’s patients reporting a doctor visit, 2%
reported a needle aponeurotomy to treat a hand symptom;
of these, 57% reported one needle aponeurotomy, 32%
reported two needle aponeurotomies, and 11% reported
three or more needle aponeurotomies (Table 6). The first
needle aponeurotomy was performed by a hand specialist/
hand surgeon in 45% of the patients reporting a needle
aponeurotomy and by an orthopedic specialist or orthopedic
surgeon in 32%.
Of those Dupuytren’s patients who reported the time of
needle aponeurotomy and the first noticed hand symptom
or diagnosis (n=34), the mean time from first noticing a
hand symptom until first needle aponeurotomy was
19.4 months (SE=6.5 months), and the mean time from
first diagnosis to first needle aponeurotomy is not reported
here given the small number of patients providing complete
data (n=4).
Summary of Treatment Effectiveness
For surgery and needle aponeurotomies, additional infor-
mation from patients was collected on their effectiveness
(Table 6). Of patients having had surgery performed by any
doctor, 80% reported when asked that the first surgery
corrected the hand symptoms. The corresponding percent-
age for a needle aponeurotomy was 39%. However, this
information should be considered carefully due to the fact
that improvement was self-reported by each patient and not
measured objectively.
Discussion
The primary goals of the research study presented in this
paper were to estimate the prevalence and incidence of
Dupuytren’s in the general US adult population as well as
to describe symptom progression and treatment patterns
associated with this condition. As expected, the prevalence
and incidence of diagnosed patients was very low (0.5%),
but higher prevalence estimates were found when patients
who self-reported a diagnosis, treatment, or any hand
symptom were considered (11%). This study is the first
large-scale study of a representative sample of the US
population, and the estimates derived using the more
stringent definitions are generally consistent with the 4–
6% prevalence rates found in other studies of general
populations [3, 6, 25].
The incidence proportion of Dupuytren’s in the general
US population estimated that the annual number of new
cases of physician-diagnosed disease, based on 2007 data,
was approximately 3 cases per 10,000 adults. The estimated
incidence of Dupuytren’s in the USA appears to be
comparable with the estimated incidence (34.4 per
100,000) for the British population in 2004 among men
aged 40–84 years [12].
In the phase 2 survey, more than two thirds of
Dupuytren’s patients reported having a hard bump on
one or both hands. In addition, one third reported that
their hand symptoms interferedw i t he v e r y d a ya c t i v i t i e s .
Yet nearly 40% of those reporting a diagnosis, treatment,
or a hand symptom indicated they had never sought
medical treatment.
Of those patients seeking treatment for a hand symptom,
over one third did not seek treatment immediately, with the
average time from first noticing a symptom until seeing the
first doctor being approximately 2 years. In general,
patients who did seek treatment initially went to their
PCP. Only 9% of those seeking treatment for hand
symptoms reported receiving a diagnosis of Dupuytren’s
disease. Other initial diagnoses reported by patients for
their hand symptoms include arthritis or rheumatoid
arthritis, carpal tunnel syndrome, tendonitis, and trigger
finger. It is not clear from the data in the current study if
other diagnoses given by physicians were accurate diagno-
ses of the patient’s symptoms at the time of assessment, if
physicians or patients confused Dupuytren’sw i t ho t h e r
similar conditions, and/or if no diagnosis was given
because no conclusion was made about the hand
symptoms. The difference in prevalence between hand
symptoms and an actual diagnosis of Dupuytren’si nt h e
current study suggests that Dupuytren’s may be under-
diagnosed. Recognition of symptoms and accurate diag-
nosis by physicians is critical as early detection and
treatment may help slow the disease’s progression. These
data indicate the need for increased physician awareness,
particularly by PCPs, of Dupuytren’s hand symptoms and
available treatments.
Both surgical and nonsurgical treatment options (includ-
ing needle aponeurotomies/injections) are currently used to
treat Dupuytren’s. Of the Dupuytren’s patients reporting a
doctor visit, 20% of patients reported one or more hand
surgeries. Most surgeries were performed by a hand
specialist or hand surgeon, and fasciectomy was the most
frequent type of surgery performed. In the literature,
surgery is the most common treatment for Dupuytren’s
[15–17, 21], and fasciectomy is the most common
procedure [15]. Prolonged postoperative rehabilitation,
including hand therapy and splinting to improve the range
of motion of the hand, is necessary to maintain the benefits
of surgery [7, 15]. The potential benefits of surgery must be
balanced with possible surgical complications, including
injury to the tendon, digital nerve, or artery; potential loss
of a finger; infection; hematoma; loss of grip strength or
flexion; recurrence of contracture; complex regional pain
156 HAND (2011) 6:149–158syndrome; skin necrosis; wound healing complications; and
joint stiffness [7, 14, 15]. A 20-year review of surgical
complications associated with fasciectomy found overall
surgical complication rates ranging from 3.6% to 39.1%
[5].
Surgery to treat a hand symptom was used more
commonly than needle aponeurotomies, and patients’
reports of treatment effectiveness were greater for surgery
(80%) than for needle aponeurotomies (39%). Only 2% of
the Dupuytren’s patients who had seen a doctor reported at
least one needle aponeurotomy to correct a hand symptom.
Percutaneous and needle fasciotomy are considered treat-
ment options for Dupuytren’s; however, high-quality
clinical studies of the effectiveness of these interventions
are not readily available [18]. More recently, the results of
studies using collagenase therapy, which involves injection
of clostridial collagenase into cords, appear promising for
the treatment of Dupuytren’s[ 1, 11, 21]. An effective
nonsurgical treatment for Dupuytren’ss u c ha st h i sw o u l d
avert surgery-related morbidity and complications. As
this study was conducted prior to the widespread
availability of clostridial collagenase as a therapeutic
agent, it will be of interest in the future to determine how
the availability of this nonsurgical treatment option may
affect the overall treatment pattern for patients with
Dupuytren’sd i s e a s e .
The main strength of the current study is that it uses a
large population-based sample representative of US adults
to provide prevalence and incidence proportion estimates
for a relatively rare condition, which were not previously
available. Additional study strengths include a high
response rate, the inclusion of many variables to describe
treatment-seeking behavior and therapies received, real-
life pictures to aid in detecting the presence of various
hand symptoms, and utilization of different criteria to
compute prevalence and incidence proportion estimates
to allow for both conservative and more liberal esti-
mates. Compared with the US Current Population Survey
data [22], the phase 1 sample had older participants on
average, had a higher percentage of whites, and had a
higher percentage completing more than a high school
level of education. To account for the potential influence
of the demographic differences, statistical weights were
applied when estimating the prevalence and incidence of
Dupuytren’s.
S o m ec a u t i o ns h o u l db eu s e di ni n t e r p r e t i n gt h e s e
prevalence and incidence findings. The analyses are
exclusively based on the use of self-reported data instead
of clinical assessment of Dupuytren’s disease. Although the
survey included real-life pictures of each symptom to help
patients accurately assess the presence of these symptoms,
there is potential for the symptoms included in the more
liberal definitions of Dupuytren’s disease (e.g., definitions 4
and 5: hard bump, dimpling) to be confused with other
conditions that are more prevalent, such as rheumatoid
arthritis or osteoarthritis. Thus, it is possible that the
corresponding prevalence estimates based on the less severe
hand symptoms, such as hard bump and dimpling (defi-
nitions 4 and 5), may overestimate the true prevalence of
Dupuytren’s disease.
Although the initial sample size for phase 1 was large,
some of the data were based on small numbers of
participants and/or rare events. In addition, all survey
respondents who reported a diagnosis or surgical procedure
(including needle aponeurotomies/injection procedures) in
phase 1 were invited to participate in phase 2 (a random
sample from those reporting symptoms only were selected
to complete a survey). Oversampling was required to ensure
that an adequate number of participants for rare events were
included in the full survey. Thus, results may potentially be
based on a patient sample more severe (on average) as
compared with the general patient population. Therefore,
the weighted average of the stratum-specific estimates was
used to account for the oversampling. Nevertheless, the
data obtained from the current study are rich and should
provide a wealth of information in designing future studies
and/or performing complex analyses.
Conclusions
We found the use of a Web-enabled panel an effective and
efficient way to conduct a large, population-based survey of
a rare medical condition. Data collected from this large-
scale survey of a representative sample of participants in
the general US population can provide critical information
needed to improve understanding, recognition, and treat-
ment of Dupuytren’s disease. The results from the current
study indicate a number of unmet medical needs in this
area, with particular emphasis on the need for better
recognition of symptoms for both patients and clinicians,
including education for non-hand specialists.
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